AMNEAL PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B | $1.99B | $1.63B | $1.66B |
| Cost of Revenue | $1.91B | $1.77B | $1.57B | $1.43B | $1.32B | $1.33B | $1.15B | $938.8M |
| Gross Profit | $1.11B | $1.02B | $820.6M | $784.7M | $769.0M | $628.4M | $353.0M | $716.4M |
| Gross Margin | 36.9% | 36.5% | 34.3% | 35.5% | 36.7% | 31.5% | 21.7% | 43.1% |
| Operating Expenses | ||||||||
| Research & Development | $186.2M | $190.7M | $164.0M | $195.7M | $201.8M | $179.9M | $188.0M | $194.2M |
| SG&A Expense | $526.8M | $476.4M | $429.7M | $399.7M | $365.5M | $326.7M | $289.6M | $227.8M |
| Operating Income | $394.1M | $249.3M | $204.4M | $-94.9M | $152.7M | $91.2M | $-248.7M | $-19.7M |
| Operating Margin | 13.1% | 8.9% | 8.5% | -4.3% | 7.3% | 4.6% | -15.3% | -1.2% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $139.2M | $-55.0M | $-40.3M | $-248.1M | $31.4M | $-35.8M | $-220.2M | $-202.7M |
| Income Tax Expense | $11.3M | $18.9M | $8.5M | $6.7M | $11.2M | $-104.4M | $383.3M | $-1.4M |
| Net Income | $72.1M | $-116.9M | $-84.0M | $-270.6M | $13.2M | $67.8M | $-603.6M | $-19.7M |
| Net Margin | 2.4% | -4.2% | -3.5% | -12.2% | 0.6% | 3.4% | -37.1% | -1.2% |
| EPS (Basic) | $0.23 | $-0.38 | $-0.48 | $-0.86 | $0.07 | $0.62 | $-2.74 | $-0.16 |
| EPS (Diluted) | $0.22 | $-0.38 | $-0.48 | $-0.86 | $0.07 | $0.61 | $-2.74 | $-0.16 |
| Shares Outstanding (Basic) | 313.4M | 309.0M | 176.1M | 150.9M | 148.9M | 147.4M | 132.1M | 127.3M |
| Shares Outstanding (Diluted) | 324.8M | 309.0M | 176.1M | 150.9M | 151.8M | 148.9M | 132.1M | 127.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |